JP6862422B2 - 組み合わせおよびその使用 - Google Patents

組み合わせおよびその使用 Download PDF

Info

Publication number
JP6862422B2
JP6862422B2 JP2018508728A JP2018508728A JP6862422B2 JP 6862422 B2 JP6862422 B2 JP 6862422B2 JP 2018508728 A JP2018508728 A JP 2018508728A JP 2018508728 A JP2018508728 A JP 2018508728A JP 6862422 B2 JP6862422 B2 JP 6862422B2
Authority
JP
Japan
Prior art keywords
lymphoma
antibody
sequence
seq
hodgkin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018508728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523685A (ja
Inventor
エンデル，ヤン
ヴィンダーリッヒ，マルク
ボックスハマー，ライナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MorphoSys GmbH
Original Assignee
MorphoSys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MorphoSys GmbH filed Critical MorphoSys GmbH
Publication of JP2018523685A publication Critical patent/JP2018523685A/ja
Priority to JP2021059383A priority Critical patent/JP2021113194A/ja
Application granted granted Critical
Publication of JP6862422B2 publication Critical patent/JP6862422B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
JP2018508728A 2015-08-21 2016-08-18 組み合わせおよびその使用 Active JP6862422B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021059383A JP2021113194A (ja) 2015-08-21 2021-03-31 組み合わせおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15181925 2015-08-21
EP15181925.7 2015-08-21
PCT/EP2016/069571 WO2017032679A1 (en) 2015-08-21 2016-08-18 Combinations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021059383A Division JP2021113194A (ja) 2015-08-21 2021-03-31 組み合わせおよびその使用

Publications (2)

Publication Number Publication Date
JP2018523685A JP2018523685A (ja) 2018-08-23
JP6862422B2 true JP6862422B2 (ja) 2021-04-21

Family

ID=54010888

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018508728A Active JP6862422B2 (ja) 2015-08-21 2016-08-18 組み合わせおよびその使用
JP2021059383A Pending JP2021113194A (ja) 2015-08-21 2021-03-31 組み合わせおよびその使用
JP2023054891A Pending JP2023093495A (ja) 2015-08-21 2023-03-30 組み合わせおよびその使用
JP2025093012A Pending JP2025131697A (ja) 2015-08-21 2025-06-04 組み合わせおよびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021059383A Pending JP2021113194A (ja) 2015-08-21 2021-03-31 組み合わせおよびその使用
JP2023054891A Pending JP2023093495A (ja) 2015-08-21 2023-03-30 組み合わせおよびその使用
JP2025093012A Pending JP2025131697A (ja) 2015-08-21 2025-06-04 組み合わせおよびその使用

Country Status (23)

Country Link
US (3) US11224654B2 (https=)
EP (2) EP3954388A1 (https=)
JP (4) JP6862422B2 (https=)
KR (2) KR102786010B1 (https=)
CN (2) CN107921129B (https=)
AU (3) AU2016311136B2 (https=)
CA (1) CA2995738A1 (https=)
CY (1) CY1124706T1 (https=)
DK (1) DK3337506T3 (https=)
ES (1) ES2891336T3 (https=)
HR (1) HRP20211291T1 (https=)
HU (1) HUE056408T2 (https=)
IL (2) IL257345B2 (https=)
LT (1) LT3337506T (https=)
MX (2) MX392561B (https=)
PL (1) PL3337506T3 (https=)
PT (1) PT3337506T (https=)
RS (1) RS62260B1 (https=)
RU (1) RU2767063C2 (https=)
SI (1) SI3337506T1 (https=)
SM (1) SMT202100541T1 (https=)
WO (1) WO2017032679A1 (https=)
ZA (1) ZA201801052B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023093495A (ja) * 2015-08-21 2023-07-04 モルフォシス・アーゲー 組み合わせおよびその使用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301786B2 (en) 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
HRP20231229T1 (hr) 2017-05-31 2024-02-02 Morphosys Ag Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje
WO2019011918A1 (en) 2017-07-10 2019-01-17 International - Drug - Development - Biotech TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
KR20200030337A (ko) * 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
EP4051317A1 (en) * 2019-10-31 2022-09-07 MorphoSys AG Sequential anti-cd19 therapy
CA3203587A1 (en) * 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
TW202334231A (zh) * 2021-12-22 2023-09-01 德商莫菲西斯公司 抗cd19抗體療法的治療範例

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
ES2788383T3 (es) 2000-04-25 2020-10-21 Icos Corp Inhibidores de delta fosfatidilo-inositol 3-quinasa humana
CA2422076A1 (en) 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
US20080152649A1 (en) * 2002-03-01 2008-06-26 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
RU2476441C2 (ru) 2007-10-19 2013-02-27 Сиэтл Дженетикс, Инк. Cd19-связывающие средства и их применение
EP2398829A2 (en) 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
EP2445530B1 (en) 2009-06-24 2016-09-07 The Feinstein Institute for Medical Research Method for treating chronic lymphocytic leukemia
CN107227335A (zh) * 2009-10-27 2017-10-03 安进研发（慕尼黑）股份有限公司 用于施用CD19xCD3双特异性抗体的给药方案
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
AU2011316917B2 (en) * 2010-10-22 2016-02-25 Seagen Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
HUE058855T2 (hu) 2011-08-16 2022-09-28 Morphosys Ag Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával
PL2744515T3 (pl) 2011-08-16 2022-05-30 Morphosys Ag Terapia skojarzona przeciwciałem anty-cd19 i iperytem azotowym
SI2834241T1 (sl) 2012-03-05 2021-06-30 Gilead Calistoga Llc Polimorfne oblike (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilkinazolin-4(3H)-ONA
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
CA2900658A1 (en) 2013-02-15 2014-08-21 3M Innovative Properties Company System and method for making pleated filter media
JP2017519757A (ja) 2014-06-16 2017-07-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． 慢性リンパ球性白血病（ｃｌｌ）の処置
LT3302550T (lt) 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
SMT202100541T1 (it) 2015-08-21 2021-11-12 Morphosys Ag Combinazioni e loro usi
RS62155B1 (sr) 2016-05-30 2021-08-31 Morphosys Ag Postupci predviđanja terapijske koristi anti-cd19 terapije kod pacijenata
SI3475303T1 (sl) 2016-06-27 2021-12-31 Morphosys Ag Formulacija protitelesa proti CD19
IL301786B2 (en) 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
HRP20231229T1 (hr) 2017-05-31 2024-02-02 Morphosys Ag Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
MX2021013101A (es) 2019-05-03 2022-01-04 Morphosys Ag Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk.
TWI865644B (zh) 2019-10-31 2024-12-11 德商莫菲西斯公司 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
EP4051317A1 (en) 2019-10-31 2022-09-07 MorphoSys AG Sequential anti-cd19 therapy
US20210130461A1 (en) 2019-10-31 2021-05-06 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
US20230014026A1 (en) 2020-06-22 2023-01-19 Morphosys Ag Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
CA3203587A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
US20220184208A1 (en) 2020-12-04 2022-06-16 Morphosys Ag Anti-cd19 combination therapy
TW202334231A (zh) 2021-12-22 2023-09-01 德商莫菲西斯公司 抗cd19抗體療法的治療範例

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023093495A (ja) * 2015-08-21 2023-07-04 モルフォシス・アーゲー 組み合わせおよびその使用

Also Published As

Publication number Publication date
RU2018107929A3 (https=) 2020-01-14
IL297057B2 (en) 2025-11-01
RU2767063C2 (ru) 2022-03-16
PT3337506T (pt) 2021-09-24
MX2022006154A (es) 2022-10-07
MX2018002241A (es) 2018-03-23
KR102786010B1 (ko) 2025-03-26
IL297057A (en) 2022-12-01
RS62260B1 (sr) 2021-09-30
AU2022202800B2 (en) 2024-01-04
BR112018003263A2 (pt) 2018-09-25
HK1247122A1 (zh) 2018-09-21
JP2018523685A (ja) 2018-08-23
AU2022202800A1 (en) 2022-05-19
WO2017032679A1 (en) 2017-03-02
SMT202100541T1 (it) 2021-11-12
US12194095B2 (en) 2025-01-14
AU2016311136B2 (en) 2022-02-17
US11224654B2 (en) 2022-01-18
AU2016311136A1 (en) 2018-03-01
CN115054697A (zh) 2022-09-16
EP3954388A1 (en) 2022-02-16
KR20240052084A (ko) 2024-04-22
KR20180042335A (ko) 2018-04-25
ZA201801052B (en) 2021-05-26
MX392561B (es) 2025-03-24
PL3337506T3 (pl) 2022-01-03
LT3337506T (lt) 2021-10-11
CN115054697B (zh) 2024-06-11
DK3337506T3 (da) 2021-09-06
IL297057B1 (en) 2025-07-01
IL257345B (en) 2022-11-01
HUE056408T2 (hu) 2022-02-28
JP2021113194A (ja) 2021-08-05
IL257345A (en) 2018-03-29
EP3337506B1 (en) 2021-07-21
CN107921129A (zh) 2018-04-17
CA2995738A1 (en) 2017-03-02
CY1124706T1 (el) 2022-07-22
US20250195646A1 (en) 2025-06-19
RU2018107929A (ru) 2019-09-23
JP2023093495A (ja) 2023-07-04
US20180228893A1 (en) 2018-08-16
ES2891336T3 (es) 2022-01-27
SI3337506T1 (sl) 2021-12-31
HRP20211291T1 (hr) 2021-12-10
US20220088197A1 (en) 2022-03-24
EP3337506A1 (en) 2018-06-27
AU2024202109A1 (en) 2024-05-02
NZ739706A (en) 2025-02-28
IL257345B2 (en) 2023-03-01
JP2025131697A (ja) 2025-09-09
CN107921129B (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
AU2022202796B2 (en) Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
US12194095B2 (en) Combinations and uses thereof
HK1251152A1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
HK40069168A (en) Combinations and uses thereof
HK40023127A (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
HK1247122B (en) Combinations and uses thereof
BR112018003263B1 (pt) Combinação sinérgica

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210331

R150 Certificate of patent or registration of utility model

Ref document number: 6862422

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250